Skip to main content
Go Back to System Level

Welcome to the University of Maryland Medical Center Newsroom. In this section, you can find the latest news releases, media team contact information and additional resources for journalists.

Contact the Media Team

  • During Business Hours: Call 410-328-8919 or email media@umm.edu
  • After Business Hours: Email media@umm.edu (monitored every day, 24/7). This is the quickest way to reach a member of the media relations staff. Urgent messages will receive immediate attention.
Clear
Showing 1-10 of 225

R Adams Cowley Shock Trauma Center Surgeon to Co-Lead Large International Clinical Trial to Determine Most Effective Treatment for Common Hip Fracture in Older Adults

February 07, 2025
A new $10.8 million multicenter clinical trial co-led by Gerard Slobogean, MD, MPH, an orthopaedic trauma surgeon at the R Adams Cowley Shock Trauma Center at the University of Maryland Medical Center (UMMC), will determine if hip replacement surgery, also known as hip arthroplasty, produces better outcomes for patients ages 60 and older than simpler “internal fixation” that has been performed for decades. 

University of Maryland Greenebaum Comprehensive Cancer Center Offers Novel Next-Generation CAR T-cell Therapy for B-cell Lymphomas in First-in-Human Clinical Trial

November 25, 2024
Researchers at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) are conducting a first-in-human clinical trial of a novel next-generation CAR T-cell therapy to treat patients with recurrent or difficult-to-treat B-cell lymphomas, which are cancers of the lymphatic system.
University of Maryland Medical Center - Cancer

Early Results from Multiple Myeloma Clinical Trial Prove Cancer Drug Combination Provides Longer Response and Potential Benefit in Disease-Free Survival

October 02, 2024
Patients with multiple myeloma, a type of cancer in their white blood cells, have a significantly longer disease-free period and likely long-term survival if they are treated with the monoclonal antibody drug daratumumab along with the standard therapy drug lenalidomide compared to the standard therapy alone.
University of Maryland Medical Center - Cancer
Showing 1-10 of 225
Results per Page

In This Section: